Skip to Content

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

In this MEDtalk Dr. Gabriel Brisou shares findings from the Descartes registry on the use of axi-cel (CAR-T cell therapy) for treating patients with large B-cell lymphoma in a second-line setting. Since July 2022, over 200 patients in France have been treated, showing an overall response rate of around 80% and 66% achieving complete remission. Despite a short median follow-up time of three months, the early data suggest efficacy comparable to previous trials, offering new opportunities for patients unresponsive to initial therapies.

Gabriel Brisou

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top